Kornimate/medical-research-clean huggingface dataset:
spasticity and treatment satisfaction among stroke survivors

Conditions: Spasticity as Sequela of Stroke

Summary: to investigate, through ethnography, changes in symptom burden and disability and their effects/interference on patient functioning, ability to perform activities of daily living (adl) and quality of life (qol) throughout the duration of one bont-a treatment cycle.


Eligibility criteria:
inclusion criteria: * diagnostic of post-stroke spasticity more than three months prior to inclusion * at least 6 months on treatment (or two treatment cycles) with bont-a injections for spasticity according to the decision of the physician * previous bont-a injection cycles did not last for more than 16 weeks * ambulatory (use of walking aids is acceptable) exclusion criteria: * neurological disorder other than stroke * spasticity-specific treatment changes within 3 months prior to inclusion * patients who had undergone neurolysis or surgery to the affected limb within 6 months * concurrent participation in a clinical trial for the treatment of spasticity
studying biomarkers in blood samples from patients with invasive cervical cancer

Conditions: Cervical Cancer

Summary: rationale: studying samples of blood from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. it may also help doctors predict how well patients will respond to treatment. purpose: this research study is looking at biomarkers in blood samples from patients with invasive cervical cancer.

objectives: primary * to develop a serum proteomic profile for cervical cancer using banked pre-treatment serum specimens from patients with invasive cervical cancer and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis. secondary * to develop a serum proteomic profile for cervical cancer using banked post-treatment serum specimens from these patients and to determine if this serum proteomic profile has possible utility in cervical cancer prognosis. outline: this is a multicenter study. banked serum specimens are used to generate proteomic profiles.

Eligibility criteria:
disease characteristics: * histologically confirmed invasive adenocarcinoma, squamous cell carcinoma, or adenosquamous cell carcinoma of the cervix * stage iib, iii, or iva disease * eligible and evaluable for gog-0191 * pre- and/or post-treatment serum specimens available for proteomic analysis patient characteristics: * patient has given consent to allow their specimen(s) to be used for future cancer research prior concurrent therapy: * see disease characteristics

Keywords: stage iib cervical cancer stage iii cervical cancer stage iva cervical cancer cervical adenocarcinoma cervical adenosquamous cell carcinoma cervical squamous cell carcinoma
appropriation of the connected solution freestyle libre® in adult patients with diabetes in the context of therapeutic education

Conditions: Diabetes

Summary: following the proposal to self-monitor by the freestyle libre® (fsl) connected object, in diabetic patients in the context of therapeutic education, regarding the appropriation of fsl, what works, for which patients , in what specific contexts and by what mechanisms does it govern? a multicentric observational research will be conducted with mixed method design (follow-up using patient questionnaires) and semi-structured interviews of patients and caregivers.


Eligibility criteria:
inclusion criteria: * patients * have type 1 or type 2 diabetes (as included in the education program), * be of legal age (over 18 years old), * do not present legal protection measures due to incapacity (such as guardianship or guardianship). * be able to read and speak french (elementary school level) * be eligible for fsl prescription and authorize the sharing of your data in libreview® * be affiliated to a social security scheme * have an email address or a phone allowing internet use * caregivers * be registered on the roll of his professional order * hold the certificate of 40 hours of training in therapeutic education. * practice therapeutic education on a regular basis exclusion criteria: * patients * presenting contraindications to the use of freestyle libre® (known allergies to adhesive products, coagulation disorders, not treated with insulin therapy or with less than 3 insulin injections per day or continuously, not requiring glycemic monitoring or less than 3 times a day) * patient refusing to follow the education program, * minors, patients under administrative or judicial supervision) * pregnant women, * patients who cannot be contacted in an emergency, * persons in a position to give their consent but with an inability to read / write the french language. * patients who do not have an email address or a phone allowing internet use. * caregivers * failure to register with the professional order (except those of the army health service who are exempt) * non-possession of the 40-hour therapeutic education training certificate. * not practicing fsl education
is the 4mgs a useful outcome measure post-ppci

Conditions: Acute Myocardial Infarction

Summary: this study aims to assess usual walking speed (4-metre gait speed) in patients undergoing primary percutaneous coronary intervention (pci) for acute myocardial infarction and to assess whether this can predict future cardiovascular events and death.


Eligibility criteria:
inclusion criteria: * any patient hospitalised with an acute myocardial infarction who has undergone primary percutaneous coronary intervention * capacity to consent * able to walk * age over 18 years exclusion criteria: * significant co-morbidities that would limit exercise capacity or make exercise unsafe (e.g. neuromuscular disease, severe hip/lower limb joint pain, peripheral vascular disease, lower limb amputation)

Keywords: percutaneous coronary intervention
lutein and alzheimer's disease study

Conditions: Alzheimer's Disease

Summary: oxidative damage by free radicals may be involved in causing alzheimer's disease (ad). free radicals may lead to death of nerve cells and decline in brain function. certain antioxidants may suppress this free radical damage associated with ad. carotenoids are a family of naturally occurring antioxidants that have important functions for human health. carotenoids are known to reduce oxidative damage, but their effects have not been studied in ad patients. the objective of the study is to examine whether lutein supplementation helps to reduce oxidative damage from free radicals in ad patients.


Eligibility criteria:
inclusion criteria: * diagnosed with moderately severe alzheimer's disease
observed outcomes associated with fluticasone propionate/salmeterol xinafoate or inhaled corticosteroids in asthma patients

Conditions: Asthma

Summary: this is an observational retrospective analysis of linked pharmacy and medical claims data from ims health/pharmetrics database. which is a comprehensive, de-identified united states (us) healthcare claims database that is representative of the non-elderly, insurance-carrying population, the total population is 35.4 million. the average length of follow-up is 2.7 years mean (2.2 years median). subjects will be identified in the database that have at least one icd-9 diagnostic code (493.xx) for asthma and at least 1 asthma treatment within a 12-month period prior to the index use of fluticsasone propionate/salmeterol xinafoate or inhaled corticosteroids. subjects will be followed in the database until they have the event of interest (asthma-related emergency department visit, hospitalization, or oral corticosteroid use or combination of asthma-related emergency department/hospitalization or asthma-related emergency department/hospitalization/oral corticosteroids) or until they are lost to follow up whichever comes first. subjects can be censored if they leave the database, have the event of interest, or are dispensed another asthma controller other than the medication of interest. all outcomes will be assessed in the follow-up period. time-dependent statistical models adjusting for differences in baseline (pre-index) asthma and patient demographics will be used to compare asthma events.


Eligibility criteria:
inclusion criteria: * one or more medical claims with a diagnosis (primary or secondary) of asthma (icd-9-cm 493.xx) during study period; * one or more outpatient pharmacy claims during the study for one or more of the following "study medications": * fluticasone propionate/salmeterol xinafoate 250 mcg/50 mcg or 100mcg/50mcg combinations * fluticasone propionate 110 mcg or 220 mcg * one or more asthma exacerbations (asthma-related hospitalization or emergency department visit, oral corticosteriod prescription drug claim, or a combination of any of the above events) during the 12 months prior to the index date ("pre-index period") or * five or more prescriptions for a short-acting beta agonist during the pre-index period. exclusion criteria: * patients with more than one of the study medications during the 3-month period beginning with the index date; * one or more prescriptions within three months of index date (pre or post) for an ics or laba other than the study medications * one or more prescriptions within three months of post index date for: * any asthma maintenance medication * any medical claims during study period with a diagnosis of: chronic obstructive pulmonary disease (copd) (icd-9-cm 491, 492, or 496); or respiratory tract cancer (icd-9-cm 160-164, or 231)

Keywords: outcomes observational retrospective database asthma
ebmt adwp prospective non interventional study : autohsct in ssc patients

Conditions: Autoimmune Diseases

Summary: the purpose of this study is to assess the effectiveness of autologous hematopoietic stem cell transplantation (ahsct) for early severe or rapidly progressive systemic sclerosis (ssc) as currently performed by different study protocols used across europe in various ebmt centres through the careful recording and analysis of routinely collected clinical and biological data.

different protocols are used in the different centres, it is not yet clear which approach will be the most efficient and the safest. every centre will follow its own local protocol for ahsct which usually refers to the recent update of the ebmt guidelines for hsct in autoimmune disease. patient selection for ahsct treatment technique with regard to the risk/benefit balance has to be carefully addressed by standard patient pretransplant evaluation, whereas treatment local regimen, follow-ups evaluation, supportive medication and prophylaxis will be recorded and analysed.

Eligibility criteria:
inclusion criteria: * autologous hsct * age between 18 and 65 years at time of transplant. * established diagnosis of progressive systemic sclerosis according to ara-criteria exclusion criteria: * pregnancy or inadequate contraception * severe concomitant disease * reduced lung function * previously damaged bone marrow * uncontrolled severe infection * severe concomitant psychiatric illness

Keywords: autoimmune diseases systemic sclerosis autologous hematopoietic stem cell transplant
efficacy and safety of ql1012 in women for assisted reproductive treatment

Conditions: Infertility

Summary: the study is conducted to confirm equivalence between ql1012 (a new biosimilar formulation of recombinant human follicle-stimulating hormone) and gonal-f® with respect to the number of oocytes retrieved in women for assisted reproductive treatment.


Eligibility criteria:
inclusion criteria: 1. signed informed consent 2. aged 20 \~ 39 years(inclusive) 3. body mass index (bmi) between 18\~30 kg/m2(inclusive) 4. regular menstrual cycle (25\~35 days) 5. basal fsh \< 10 iu/l (menstrual cycle day 2\~5) exclusion criteria: 1. history of ≥3 previously completed ivf/icsi-et cycles without clinical pregnancy 2. history of ≥3 recurrent spontaneous miscarriages 3. patients with high risk of ovarian hyperstimulation syndrome (ohss) 4. primary ovarian failure or poor responders to ovarian stimulation 5. presence of pregnancy in previous 3 months 6. presence of clinically significant systemic disease, endocrine disease or metabolic abnormalities 7. history of malignant tumors of the ovary, breast, uterus, hypothalamus, pituitary gland, etc.;
hd-tdcs combined with circadian rhythm reconstruction and micro expression changes on consciousness recovery in patients with chronic disturbance of consciousness

Conditions: Disorder of Consciousness

Summary: the circadian rhythm characteristics of sleep cycle and neuroendocrine in patients with chronic disorder of consciousness show different degrees of disorder, and the relationship between this disorder and consciousness level is unclear.the researchers used hd-tdcs to treat patients with chronic disturbance of consciousness who intervened in circadian rhythm, and used a variety of methods such as eeg, fmri, protein metabolism, erp and micro-expression to explore the mechanism of improving the state of consciousness of hd-dcs and the relationship between circadian rhythm and patients' consciousness level

the sleep status (\> 24 hours) of patients with chronic disturbance of consciousness was recorded with the revised coma recovery scale revised (crs-r) and polysomnography (psg). the sleep cycle of patients with chronic disturbance of consciousness was judged by the open and close eyes cycle and eeg. patients with circadian rhythm treated with or without blue light stimulation and melatonin were treated with hd-tdcs. eeg, fmri, protein metabolism, erp and micro expression data were recorded before and after treatment.explore the mechanism of improving the state of consciousness of hd-dcs and the relationship between circadian rhythm and patients' consciousness level

Eligibility criteria:
inclusion criteria: * patients with diagnosis of disorder of consciousness * stable vital signs * good coordination, less spontaneous activity * no anti-epileptic and sedative drugs taken within prior 24 hours * the family members volunteered and signed the informed consent exclusion criteria: * locked-in syndrome * diseases and factors that may affect the judgment of brain function, such as metabolic diseases, poisoning, shock, etc. * there are contraindications to mri scanning, such as the presence of metal implants in the body * contraindications treated by transcranial direct current stimulation

Keywords: disorder of consciousness circadian rhythm hd-tdcs
beta-hydroxybutyrate feasibility treating ibd

Conditions: Crohn's Disease; Inflammatory Bowel Diseases

Summary: this clinical trial aims to understand the feasibility of patients taking ketone body supplement beta-hydroxybutyrate (bhb) for 4 weeks with a confirmed diagnosis of crohn's disease and starting new therapy for active disease. the main questions it aims to answer are: * bhb supplementation will be feasible and acceptable to patients. * bhb supplementation will be associated with a reduction in systemic inflammation. * bhb supplementation will be associated with a reduction in pro-inflammatory bacterial colonies. participants will: * take 3 capsules x 3 times per day for 4 weeks. * document food consumption using a 24-hour food recall questionnaire. * provide blood and fecal samples twice, at the beginning of the study and the 4-week mark. researchers will compare the group taking the ketone body supplement and the group not taking the supplement to see if the supplement provides relief of symptoms suffered from crohn's disease.

a clinical trial designed to determine the feasibility of prebiotic supplementation with beta-hydroxybutyrate (bhb) in crohn's patients in a prospective, open-label pilot trial and to assess the association between bhb supplementation and changes in the microbiome, inflammation, and markers of disease severity in crohn's patients in a prospective pre-/post-study design.

Eligibility criteria:
inclusion criteria: * age ≥18 years of age * confirmed diagnosis of crohn's disease * active disease defined as either a fecal calprotectin \&amp;gt;250 µg/g or active disease on endoscopy within the prior 3 months * starting a new therapy defined as a biologic (anti-tnf, anti-integrin, il-12/23, or il-23) or small molecule therapy (jak inhibitor, s1p receptor modulator) * willing to provide consent for participation. * managed at ut digestive health clinic. exclusion criteria: * any current or recent (within 4 weeks) use of bhb supplement * currently or recently (within 4 weeks) following a ketogenic diet * currently or recently (within 4 weeks) following an intermittent fasting diet * any recent antibiotic use (within 3 months) * recent infection with c. difficile (within 6 months) * current or recent (within 4 weeks) daily use of acid-suppressing therapy (proton pump inhibitor or h2 receptor blocker) * current or recent use (within four weeks) of non-dietary probiotic supplements * unwilling to provide signed consent

Keywords: beta-hydroxybutyrate (bhb) proinflammatory immune cells gut bacteria ketone body ketogenesis gut barrier integrity inflammation digestive health
safety study of galantamine in tic disorders

Conditions: Tourette's Syndrome; Motor Tic Disorder; Vocal Tic Disorder

Summary: the purpose of this study is to determine the safety, tolerability and efficacy of galantamine in tic disorders. the impact of galantamine on commonly associated behaviors (i.e. attention, obsessions, etc.) will also be examined.

modulation of cholinergic activity is a growing focus in neurologic therapeutics especially for dementing disorders such as alzheimer disease. treatment with the recently developed cholinesterase inhibitor, galantamine, has demonstrated significant improvement with few issues related to tolerability. in addition to inhibiting the activity of acetylcholinesterase, galantamine also modulates the activity of nicotinic cholinergic receptors by an allosteric mechanism. as a result, galantamine therapy may be beneficial when the response to other agents has been limited. cholinesterase inhibitor therapy has been reported to improve motor tics in children with ts refractory to more traditional therapies. symptoms of co-morbid behavioral disorders, primarily inattention, were also improved. cholinergic modulation appears a promising avenue for managing tic disorders. men and women (18 - 50 years of age) fulfilling dsm iv criteria for the diagnosis of chronic motor tic disorder, chronic vocal tic disorder or tourette syndrome and experiencing suboptimal control of tics on current therapy will be enrolled into this open label evaluation of galantamine. a total of 6 visits will be required over 22 weeks. participants will follow a standard 4 week titration schedule achieving 12 mg bid after 8 weeks. they will maintain at 12 mg bid, or the maximum tolerated dose, for a further 8 weeks and then be withdrawn from therapy. the difference in tic severity prior to and upon completion of therapy will be examined. the impact of treatment upon obsessions/compulsions, attention/concentration, depression, anxiety and quality of life will also be determined.

Eligibility criteria:
inclusion criteria: * dsm iv criteria for the diagnosis of tourette's syndrome, chronic motor or chronic vocal tic disorder * accepted method of birth control exclusion criteria: * preganancy or nursing * unstable medical illness * unstable psychiatric illness

Keywords: tourette's disorder tic
stroke rehabilitation program based on a powered lower extremity exoskeleton in chile

Conditions: Stroke

Summary: this research will study the effects of a rehabilitation program assisted by a powered lower extremity exoskeleton in patients after stroke. it will compare clinical and biomechanical features of patients at baseline and after intervention. additionally, it will also examine the use of a brain-computer-interface (bci) to command movements on the powered lower limb exoskeleton. the findings will be used to improve understanding human-robot interaction, to improve the design of the robotic devices and to improve rehabilitation services.

stroke is one of the leading causes of mortality, morbidity and disability in adults in developed countries. survivors may suffer several neurological deficits or deficiencies, such as hemiparesis, communication disorders, cognitive deficits and visuospatial perception disorders. hemiplegia is a par loss of hemi-body voluntary motricity following a brain injury, usually resulting in alterations of the locomotor system with persistent disorders of movement and posture. hemiplegia significantly affects gait performance. gait recovery is an important objective in the rehabilitation program for stroke patients.the currently available treatment techniques include classical techniques of gait rehabilitation, functional electrical stimulation, electromechanic devices, robotic devices and brain-computer interfaces, among others.the evidence suggest that the combination of different rehabilitation strategies is more effective than conventional rehabilitation techniques alone. technology-based rehabilitation methods such as robotic devices need more research to demonstrate their effects on gait recovery. this study will assess the effects of a rehabilitation program with a powered lower extremity exoskeleton in people with stroke. additionally, it will also examine the use of a brain-computer-interface (bci) to command movements on the powered lower limb exoskeleton. the findings will be used to improve understanding human-robot interaction, to improve the design of the robotic devices and to improve rehabilitation services.

Eligibility criteria:
inclusion criteria: * unilateral lower extremity paresis * haemorrhagic or ischemic stroke * a minimum of six months after the acute infarction/onset of the disease * full passive range of motion in lower extremity or at least at neutral position * be able to stand freely * be able to walk with or without aid for at least 20 meters in less than 2 minutes exclusion criteria: * peripheral nervous system pathology * epilepsy * weight over 100 kg * no cognitive ability to follow the study instructions * pregnancy * use of implanted devices * instable lower extremity joints or fixed contracture

Keywords: stroke hemiparesis gait brain-computer interface rehabilitation exoskeleton